ClinicalTrials.gg
Enrolling by invitationNCT06557928Updated Aug 16, 2024

Protocol for Evaluating Physiological and Psychological Adaptation Mechanisms in Tibetan Plateau Environments

An observational study in High Altitude, sponsored by Peking Union Medical College Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Peking Union Medical College Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
17
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study is a single-center prospective observational study. It plans to use a series of physiological and medical instruments and international common physiological and psychological questionnaires. To dynamically detect the changes of physiological and psychological adaptability of doctors in Peking Union Medical College Hospital before leaving Beijing, 1-7 days after arriving at the plateau in Tibet during the acute phase of plateau hypoxic stress, 2 weeks, 3 months, 6 months, 12 months after staying in Tibet during the chronic phase of plateau hypoxic stress, and after returning to Beijing.

02

Conditions studied

  • High Altitude

Browse trials for

Keywords

  • high altitude
  • adaptation
  • acclimatization
03

In context

Altitude Sickness

192 studies on the registry are indexed under Altitude Sickness; 45 are open to participants now.

This study's planned enrollment of 17 is below the median of 91 across 31 observational studies indexed under Altitude Sickness.

Browse Altitude Sickness studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,148 studies on the registry; 473 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Doctors in Tibet from Peking Union Medical College Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy individuals aged 20-65 years
  • They can sign a written informed consent and is willing to cooperate
  • They have the qualification to aid Tibet and meet the basic requirements of physical examination for aid to Tibet

Exclusion criteria

Exclusion Criteria:

  • Age less than 20 years or more than 65 years
  • Unable to sign a written informed consent or unwilling to cooperate
  • They do not have the qualification for supporting Tibet or do not meet the basic requirements of medical examination for supporting Tibet
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
17 participants (estimated)
Patient registry
No

Groups and cohorts

  • Doctors to Tibet from Peking Union Medical College Hospital in 2024

    Other: measurement

  • Doctors to Tibet from Peking Union Medical College Hospital in 2025

    Other: measurement

Interventions

  • Othermeasurement

    Measurement of multiple physiological indicators and psychological status and multi-omics study

06

What researchers measure

Primary outcomes

  1. help understand the physiological mechanisms and psychological changes of hypoxic adaptation

    This study is expected to increase our understanding of the physiological mechanisms and psychological changes of hypoxic adaptation mainly through analysis of multi-omics.

    Time frame: 2024-5-27~2026-12-1

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 16, 2024
StartActual
May 17, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06557928
Responsible party
DONG WU (Professor of Gastroenterology, Peking Union Medical College Hospital) — Principal investigator
First posted
Aug 16, 2024
Start date
May 17, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Aug 16, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion